Answers are grounded in this paper and cite their sources.
BACKGROUND: therapy is a new technology that helps to address the cytokine storm and to regain control over various inflammatory conditions. AIM: therapy used as an adjunctive therapy along with standard of care in septic patients admitted to intensive care unit (ICU). METHODS: value < 0.05 was considered to be statistically significant. RESULTS: therapy was safe and well tolerated with no adverse events reported. CONCLUSION: might be an effective adjuvant therapy in stabilizing sepsis and septic shock patients. However, it is advisable to start the therapy at an early stage (preferably within 24 h after onset of septic shock).
No takes yet. Share an insight, caveat, or question.
Paul et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: